Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
Debridement is a standard of care step to prepare the wound bed for healing and can help in the management of infection. It involves the removal of dead or devitalised tissue from a wound.
"We are very excited to make this strategic investment in
Mölnlycke and
"We are delighted to have Mölnlycke's support. This substantial investment will empower us to strengthen our strategic plans, creating significant long-term value for our stakeholders and help to improve standards of care for patients" said
For more information, please conatct:
Email: jennifer.doak@molnlycke.com
Phone: +1 678 206 6179
Email: ellie.hanson@finnpartners.com
Phone: +1 929 588 2008
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
https://news.cision.com/molnlycke/i/molnlycke-primary-logotype-rgb,c3319952 |
Molnlycke-Primary-Logotype-rgb |
View original content:https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-announces-us-15m-investment-in-next-generation-enzymatic-therapeutics-company-mediwound-ltd-302196800.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN61311&Transmission_Id=202407150738PR_NEWS_EURO_ND__EN61311&DateId=20240715)